Nov. 10 at 12:22 PM
$KMDA Exhibit 99.1
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
● Third Quarter Revenues of
$47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of
$11.7 Million, up 34% Year-Over Year
● Nine Month Revenue of
$135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of
$34.2 Million, up 35% Year-over-Year
● Positive Outlook for Remainder of 2025 Based on the Company’s Diverse Product Portfolio Supports Full-Year Revenue Guidance of
$178 Million-
$182 Million and
Adjusted EBITDA of
$40 Million-
$44 Million
● Generated
$17.9 Million of Cash from Operations During First Nine Months of 2025; as of September 30, 2025, had
$72.0 Million of Available Cash
● Company Continues to Focus on Advancing Business Development Opportunities to Support Continued Long-Term Annual Double-Digit Profitable Growth
● Interim Futility Analysis of the Pivotal Phase 3 InnovAATe Clinical Trial for the Inhaled AAT Therapy to be Conducted in
